KYMR - Earnings call transcript Q3 2024 | Kymera Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Kymera Therapeutics Third Quarter 2024 Results Conference Call. [Operator Instructions] Please note this event is being recorded. I would like now to turn the conference over to Justine Koenigsberg, Head of Investor Relations. Please go ahead.

Justine Koenigsberg

Thank you. Good morning, and welcome to Kymera's quarterly update call.

during are Chief Founder, Jacobs, slides Medical Financial website note morning Jared and our kymeratx.com. in this intend at IR Officer. Please our we section which Gollob, Officer; that within our me corporate Nello data is President Mainolfi, CEO; Chief to presentation, Joining reference remarks, available from the Jared's and our Bruce of

to please everyone's one time call prepared a to open questions. limit remarks, your that ask to our to questions Following follow-up the you and enough relevant assure questions. we We have will we address

recent Before that obligation in Any we about assume today's call today's our like cause differ to be no found may turn to forward-looking These risks call. With those on remind statements discussion the any that, I plans expectations, you subject and speak over prospects. actual today's A results our date, begin, that only these I statements SEC. will from description can would of future filed of statements now materially forward-looking uncertainties to will statements forward-looking as most projected. Nello. with and made include to the are to we update and risks XX-Q

Nello Mainolfi

morning, you, everybody. and Thank Justine, good

We right updates have a today, lot of jump in. important so let's

growing development. It's I first-in-class were clinical this important the First our capital our we're of whole and enter an accelerate degrader STATX oral STATX the that pipeline. moment recent excited clinic X we that path believe our increased towards to we're the industry. ever to study to and and focus also for given able highlight the extremely foremost, is of to have directing started resources KT-XXX, immunology that medicine Phase first important the we

we are just summary, like a We that in also in to that there preclinical both XXX data, Japan than well X investigational a dupilumab-like in a of wide KT-XXX more million know that a like according even potential the tolerated similarly of diseases has the in XX species models. upstream have And or have studies daily We've have degrader shown who all than market have oral U.S., you In an than to Europe vivo variety associated patients can in profile run ThX cellular an from of million in more pill. Many STATX suffer with and potently receive preclinical less IL-X safety those dupilumab. and KT-XXX block inflammation. biologics in species. and that shown patients drug dupilumab was we

office. We the refrigeration, paradigms and doctor's atopic that treatment focus frequent transform could of a syringes has to to one tens While a affect is to name believe on oral in diseases one million for on a the that access the expanding are millions dupilumab, needles, require doesn't that of patients and as is focused on EoE, of few. patients, patients pill, KT-XXX waiting medicine across X millions convenient, potential just asthma, safe roughly currently effective COPD, Kymera dermatitis, of such that trips the many

prevalent quality change ThX future. that drug families in of In life highly be many to diseases the that addition, in potential a believe given the we has will are for this children,

the at Our will in the next STATX to half share volunteer the first update we completion full study which is point healthy results. be XXXX, upon expected of of

the plan X move Following study, the is into Phase of to patients. completion quickly our

call. I industry to another of first-in-class following KT-XXX, later on Phase X with clinic briefly we is IRAKX expanded more where in This our program the the development with next directed on year. being We partner, our have influenced assets. We're on wanted studies lead Jared was first are ongoing share to able the important share several finally XXX information another stage a expect to study Phase to companies has plans that Kymera degrader. guidance run and well Sanofi. also those will other highlight provide around established, IRAKX more our success by the clinical next and details update X

I'm the read today, of our release Phase from Phase studies ranging X a you at transitioning in conclusion powered studies proof-of-concept program the right As is sure press with like dose registrational studies have to path ongoing as our accelerating studies. fully the Xb of X to earlier means Phase

to the specific partner, group X each and for We're increased Sanofi, we changes, have the to have commitment program. the Phase one to studies. added this study trial to important thankful select able basically of terms for subsequent confidence dose dose registrational In the our information being in to enough to

through ongoing to work Similar Turning in had At preclinical as to promising our programs, compounds. being as Day we well. exciting TYKX have our advanced KT-XXX progress all our parallel molecule, KT-XXX. we to on introduced TYKX, this year, of program January we development, was report lead R&D other of our and

of activity a in compelling with One by similar compounds evaluating demonstrated vivo and KT-XXX, greater we and an selectivity the more highlighted than even were profile. profile safety

result, the as new compound, advance decided we our have KT-XXX clinical lead a As candidate. to

which without Importantly, trial start half our first time the can we 'XX. assumed of that we previously the Phase stated believe TYKX in do impacting lines, development X

specifically programs. to everyone oncology wanted our update strategic with pertains broader and it to provide just as I a Finally,

As injectable compete last increased profiles profoundly and that was we terms the you of immunology it immunology. of had that by rationale we in in many year, The believe shared our oral around could safety. in efficacy we focus with biologics impactful degraders driven was could we recall, time generate first with this

focus preclinically, to in starting our KT-XXX and best-in-industry the we're resources from will next potential STATX the today, create we assets can even unveiling we and to the clinic year, KT-XXX space, be programs clinic is now think more and of develop this to with clinic, with the that close immunology we that As we KT-XXX and Xb positioned believe in more of immunology exciting in with impact believe value. into Phase to the TYKX time patients. Even our where oral with of outsized multiple other shown we portfolio KT-XXX trials, millions efforts opportunities

As encouraging we pipeline, we completed of will we a degrader, advance beyond partner. our a promising activity while as have demonstrating a and KT-XXX, made X clinical degrader tumor clinical our types, decision some our X variety Phase KT-XXX, enrollment, oncology with that progress Phase in have the result, MDMX with made we only STATX

on that when makes can we'll expect share so. to You do if it this sense and more

our exciting conclusion, impact industry. It families these in pipeline. of should that best year-end, what believe decision, our programs quite and the lightly about who While made investigators not or the trajectory had clinic with we it there in are KT-XXX take in be immunology we patients, this see to and that Kymera programs. In is our as our this has We're, within resources, We've Kymera and it focused both advanced expanding biggest grateful studies especially contributed our did patients. the approach the one XXXX, team immunology and pipeline. could noted on to the considerations we on supported many capital fact, in ultimately, become internal to thinking potential people, that decision without are

closer expanding the million TYKX session a X developed total us you through points have We and through cash our on have end into We've to advance that Bruce clinic. the approximately our of in KT-XXX $XXX and results. let Jared? looking studies. XXXX, in have will walk programs, and raised a we the pipeline. I several mid-XXXX has at share a will with here to Q&A financial our forward supported I'm Jared the third remarks. the Sanofi inflection across of degrader prepared and pause more compelling to Phase details just to And are enabled profile quarter

Jared Gollob

Thanks, Nello.

like culminating As recognize for it I'd KT-XXX healthy the advance initiation through rapid the of in Phase and IND-enabling clearance the our first-in-class this to to relates IND team to the studies, volunteer study immunology, X this program earlier month. progression first

details cohorts of MAD SAD/MAD days. includes placebo. KT-XXX take single provide now As design. compared trial healthy design, to and the trial Phase quick wanted dose X placebo The on I receives shared dose receives as many daily have or single a component, placebo. In evaluating ascending subject of the the we subject KT-XXX or volunteer SAD the overview over XX opportunity KT-XXX the multiple to a each either either each to component, of In a dose not

activity are preclinical terms saw share, in data degradation is plan level of the in we demonstrate trial degrade well skin In preclinical doses at work, are on and robustly we to is STATX tolerated. Based safe or at strong to we the more, models. which main can which XX% of targeting of that our that biologics-like blood and the objective our STATX we

to to case measured this we fact, pathway are efficacy. patient levels data shown STATX of in translatable that have the blockade, In by levels, be

this we As degradation from and and safety said, study. readouts STATX have key are tolerability the

Additionally, as on measure many impact healthy KT-XXX in these on biomarkers. we and our the fully know, volunteers study. have plan TARC certain ThX We to biomarkers, you an specifically of to expect IgE

report MAD the relevant expect true to At program. the now X the KT-XXX's results we and in share half Phase was we next to SAD is the much and KT-XXX However, also or patients, to of will in that stage before turn of XXXX. continue for full our for we first impact TYKX plans robust time, underway, also believe development. I'll be to likely as for our more enrollment dupilumab. With

thought decision we of As details KT-XXX share XXXX the half Nello the particularly candidate, time a study. I few around X KT-XXX, for the can which made we the our influenced take start to lines to to without comparison KT-XXX advance stated over believe a decision. our mentioned, new I first we clinic, the would into impacting that of development Phase a minutes some do

TYKX You any slides feature corporate XX you KT-XXX, bowel did biology our testing, and and on degradation important spared function the potent can pathways, of our in type preclinical of proteins corporate the KT-XXX disease. its IL-XX, inhibition available loss that inflammatory potential program in demonstrated of TYKX is reference presentation, and mutations. Like which the treatment potency of our website. On other on can in impact the KT-XXX interferon picomolar IL-XX human signaling, Slide and XX, recapitulate to deck, XX see JAK of also X the a IL-XX showing of Slides not

With KT-XXX. To XX. profile, back Slide to potential doses our loss IRAKX. activity predicted Importantly, KT-XXX for lower activity will to what the the as in had shown I&I at and has I was greater replicate achieve KT-XXX profile cover out of this function compared than round vivo biologics-like on TYKX KT-XXX, franchise,

regulatory Sanofi the the previously development program was X announced structure directly the Dermatitis We Atopic advancement program. support of decision taken studies, has Suppurativa ultimately Phase to And in and steps selection shorter trials. the this of expand to a has goal as trials the reminder, and with meaningfully pleased dose strategy, a accelerate necessary to that the overall are pivotal time endpoints. enable the to KT-XXX line. To to are being additional evaluated studies Phase increased to with perspective There study no X changes with size both doses Hidradenitis the

the has from patients increased the XXX and to and X X dates expanded of primary of trial evaluate XXXX XX respectively. doses KT-XXX AD, compared just to has will to HS Specifically, The versus doses been Phase and for and placebo, active evaluate just mid-XXXX previously. previously. These placebo first Phase changes XXX doses drive active will KT-XXX the to versus dose of X trial HS from completion one XXX half X patients AD X versus

the of extends pipeline readout, reduce overall at the KT-XXX safety potential studies. We're be did and a uniquely lines in that product pivotal Phase and Phase before of and impact we will to program by the [ progress obviously for with remind meaningfully it will unmet our need opportunities sharing for development I totality in representing our that immunology KT-XXX to high each faster that add time STATX data believe the want degraders Nello While too allowing to are will path expect development everyone earlier, what data that time opportunity positioned of X programs, we but ]. the oral not And energized said the we ASH by to have multiple both biologics our the the December. X on large oncology, degrader, indications. Finishing up complete I efficacy more much

stop that Hodgkin's given the was results our here will focused observed reminder, the presentation. I'll be lymphoma third a financial to As in the promising those included ask patients Bruce quarter we enrollment on review responses population, and in results. Bruce? and poster latest

Bruce Jacobs

Thanks, Jared.

financials collaboration. to morning. In have a I'm from release going on the to and turn then a provide million recognized sure SG&A, attributable to $XX finally, XX-Q, compensation, million the quarter, of then spending As the we and and lot to our -- million stock-based runway this with in we Sanofi Nello. we to the which that's have statements down was That excluding Combined quicker-than-normal and the and X% our sequentially overview on filed cover balance was quarter, of revenue. a the refer call, and this $X.X financial our the you cash-based cash I'm cash to June all many ended R&D questions, back we mid-XXXX. I'll providing all quarter. of of press now in And quarter sheet, call about noncash the you $XXX

Nello Mainolfi

Jared. and Bruce Thanks,

with value-creating look pipeline likely year. We're months next on forward The to keeping KT-XXX catalysts, us. that best-in-industry and exciting significant XX for more to therapeutics open immunology based well-resourced these enthusiastic forward to on so we about than profile preclinical our And multiple finding. We're degrader our the sharing to we're we clinic of and we're Before which Advancing you a the progress. of is and want of X look on TYKX just opportunities the our a Kymera provide call to forward and updated doing drug reiterate ever with other programs, pipeline look on more to and pipeline, with we very visibility next yet milestone the industry. have the executing will questions, to sharing providing front disclose in we to rest advance in you. updates I our

Finally, I our first-in-industry questions. on pause thank to very to wanted ambitious collaborators continuing deliver goals operator to ask and endeavors. I'll Kymera the and the team for call and to here the open

Operator

Marc question Cowen. first from of The Frahm TD Instructions] [Operator comes

Marc Frahm

where the the thinking investors changes kind Maybe comp But to on do alluded you XXX to seen of thanks profile is. TARC to a as of And this those maybe volunteer the what you be in to through clarity healthy ThX to dupi almost to? IgE ], data the [ changes with to. and a of reliable think really ago target range volunteer percent how tight and kind trying the seem need -- decade think how to thinking get you are? for do comparable was How really biomarkers, exactly and the healthy -- study from you

Nello Mainolfi

jump I'll Yes. Jared, in. start, and Maybe please

any from main PK think, demonstrate Jared, the goal So us, seen Phase X is I but is first, first amazingly I we've mean, as program, explained of for especially and that the that for study profile well-tolerated translating the the that to we predictable preclinically. have safety

Now to a with have we biomarker. in multiple unique as we've this times, access degrader, a direct opportunity done

and of they're other a biomarkers because not don't lots So modalities forget, to biomarker. proximal use companies have able downstream

protein proximal most the which levels. have is we STATX So biomarker,

only So disease pathway been IL-X/XX correlated the correlated is to protein the Again, has STATX to we block disease blood That goal that biomarker in skin of can look the impact. to been at able and blocking that pathway to impact. levels And that's the we're fully. study. show has

recent I'm partial digressing In fact, humans there if where protected ThX loss that of was STATX function paper, where they a variant a actually bit, there actually, was of sorry against found asthma. were

that's function, So protein protection time, in first levels now protein actually correlating for ThX. the to even

this with at can't and other you including biomarkers. companies, your day, So in measure back now again, companies because long-acting have also you levels, downstream look obviously direct the many Regeneron biologics, really

to other And know, like people it's haven't from by around dupilumab and recent something IgE TARC has right? to I mostly they're I in baseline. publication understand IgE elevated mostly variability. that seen and inter-subject think looked is the data companies. But I so trying just you but actually You're for is other IgE have As TARC. from companies, it's been volunteers, at measure modestly that healthy there, important phospho-STATX detected data. out There feel the

So it to of degree makes difficult it the predict reduction.

And subcu published you impacted you referring you at you see IgE IL-XX bit actually paper X. XX%, in is in variability. quite TARC XX% in to between XX%. is And So look volunteers, data dose, example, if if for from healthy the at the -- there biologics if look the dupilumab that is actually XX%. and line the that a which long-acting and XX% of you evaluated Phase look to Actually, being between with up also at is were of

in biomarker think I trying So I least would data, relationship because at the are other discourage that kind range. endeavors, of exposure the sets this people to very from just noisy. understand to -- because

So know have because pathway for again, that of be and ability we of levels that's change suppress sure in us the been confidence signaling. seen tell biomarkers, safety, the that range these but I'm the obviously is degradation we'll critical, say why has what been have to we in agents will STATX PK, is they clinic. what Then we they

Marc. answer, long Sorry,

Marc Frahm

Long but model very the helpful. more on just Then with maybe Bruce.

with kind the of of kind it's be you can side? to the any prioritization into or Just of of the immunology? from immunology there oncology Are talk that savings redeployed all going continuing through

Bruce Jacobs

Thanks, It's question. good Yes. Marc. a

mean, our I aggregate because we clinical we won't in development undertaking savings, fact are of be contemplated, the the own. there -- that, of obviously, plans So some yes, on the that

the disclosed we that we immunology be would programs the know if invested future. not our a and of the you do all, pipeline, will in part that about in haven't clinical However, the meaningful that, but both development imagine yet of ones

to change cash change in enough the So guidance. while runway, the ultimate there modest might be not a

our reinvested programs. it, I you should think of most be will immunology assume in

Operator

Patel from question next Riley. Kalpit from comes B. Our

Kalpit Patel

the ear the most you've if as looked think STATX MCXXX? [ on milligrams if reductions atopic the And derm at ] curious XX made the you've kilogram showed IgE. here. just the per in one Maybe I'm program in follow-up, in a change preclinically, thickness model, dupi the to I comparisons

So into that curious dose I'm humans? what translates

Nello Mainolfi

Yes. question. Thanks, Kalpit. Great

So let's start with second. the

XX XX in dogs, or the you months, in you the kg you mg in that a kilogram. that's monkeys really close what if to XX, So XX said, much single-digit -- per at have mouse, reach now need per so use look dose what for up dose. we looking the milligrams to at, degradation, In because basically we're slides a actually lower been XX%

in need plasma dogs, higher So the in you and -- larger mouse it's monkeys in is than why because actually dose in in is it reason humans. protein binding a mouse,

So you monkey the would the data data. I at look when and should do the the say you maybe using more will more than dog projection, dose dog show mouse.

So What we dose in don't is will be this are -- past what well. in as the -- we've are talk said projection. in explored the broadly the IRAKX about doses programs broadly that exploring probably, again, that program we we we've

So so when biomarkers we disease ThX-driven to doses. With it's on first your relatively question, we these low outcomes. run regards ThX models, focus and

in -- lungs inflammation. we lung That again, of at, and look can ThX both looked infiltrate asthma in ThX. we ] TARC is [ more disease of well IgE the cells models, And at only model other why at as where biomarker. those and look the measures that's so for not ThX model and other And we other outcome, as

because composite So ear that we for ] dupi not either outcome non-ThX of or more [ degrader monitor just something kind for thickness is well. is it's as a our

Operator

Our Truist comes Securities. from next Devarakonda question Kripa from

Alexei Siniakov

issues as TYKX, slow A studies, you inhibitor the launch for could about efficacy, psoriasis some think like investors and a future in an TYKX describe they We've trial you Do good benefit? challenges when some is efficacy provide conversations as on for had enrolling a IBD. about you citing indications consider on some asset. these TYKX would question And Alexei with what for Kripa. Siniakov in others degrader opportunity? in the think experienced expanded This and maybe like patients the address additional that enrollments would

Nello Mainolfi

recruitment Yes. address one. first the the I'll Maybe and one, Jared I'll let address

point. So I'm the bit current success differently, going inhibitors. answer your a to of point it I of bring mean, still you commercial the obviously but addressing hopefully TYKX

been at by we have a has By to a that all only function differentiated now address development. We stages be genetically from we in to are to -- receptor that by inhibitors in BMS, block would there TYKX, able companies removing understand signaling, have well-characterized people signaling, Kymera, these tend that we we're X is to So what agree TYKX at been different going they complete us to X TYKX approved industry, drugged companies. multiple because address and IL-XX, these are X with the strongly that don't interferon. or target, least One different IL-XX, near of has protein, TYKX in completely molecules they block of pathways. I are has going and biology important other right validated be of believe and X TYKX. partial actually scaffolding type the difficult function think

the like an that indications. So profile not preclinical again, that We're we for. look target even biologics with molecule active because, obviously XXX in many the would of And the our to those failed. can in have this we obviously, I looking more have translate we're name That's game is profile, profile degrader inhibitor, of degradation the with program. if full able type something of actually the if compete particular a believe we're that of for the looking

bit general really Jared, drug. right now maybe [ we're transformative space. But this have a ] about because the a TYKX fatigue it's going that point, at And recruitment? there missed any think been in I is think to ] I [ of comment

Jared Gollob

Yes.

we inhibitor, a we the and think include patients have would prior had prior I initial might likely been not to TYKX on been in TYKX on patients, but come proof-of-concept had study for who tolerability off the initial have whereas have wouldn't patients might TYKX progressed proof activity prior that our due but put understanding on who interested drug even in the concept, of through after be those who in in issues. probably we we've Further of road, the once down gone do inhibitors, we study. first progressed, patients

Nello Mainolfi

operator? question, Next

Operator

Brad next Our from of question Canino Stifel. comes

Bradley Canino

ThX replication steps for a after major that STATX shared the ThX of development? guess biomarkers will is type hitting conduct? in patients accelerate to plus degradation in sufficient I mid- hard SAD/MAD do patients And needed? clinical you disease stated likely in Or test the where much the I Is testing results to of safely. be But duration know the particular late-stage question. need will how remarks is next best endpoints? prepared dupilumab there XX% is be to and that this you

Nello Mainolfi

Brad, question. great Yes,

So this kind it of I would way. say

in I patients. at demonstrate of therapeutically is we think very that is an demonstrate the one XX% and anywhere able regards briefly And doing believe have and biomarker in STATX with STATX I think that is of really studies you especially do X a believe think can but I that activity which, the AD actually of as blocks degradation and get antagonist. relevant, safe goal of into Phase biomarker in the to skin, what skin levels that that therapeutically to excellent where relevant, reach Regeneron that the dupi well we shown does well-established patients are Sanofi that study between have signature. that dupilumab pathway we've maximal actually job ] that of see the signature, shows to done you're XX% actually blood signature there AD receptor could as as a XX%, degradation manner. I you and said, And an especially IL-X a type least context [ is relevant

to in the you be of into will population. telling allow profile move And study biomarker relevant important large patients that drug. studies a the imagine probably exceptionally could in of to all you So the

could think I an be interesting So sequence of events. that

important this quite I what ready plans validate share to to think are, we're those not opportunities our mechanism. are but

Operator

Morgan Vikram question from Purohit from next comes Stanley. Our

Gospel Enyindah-Asonye

is Gospel Vikram. This for on

on partnership look we currently expect ideal question should term? partners the And in a KT-XXX near We have partnership underway? would What KT-XXX. potential one with something be an like? discussions are and And

Nello Mainolfi

Yes, great question.

And across not that the we've happen is say ] on a companies. translation the ASH XXX, lifetime will impeccable PK/PD safety at an pipeline for. to out [ activity time and But I And oncology really or shown ongoing indications. exciting the on have we've our mentioned, poster Jared we've that into hypothetical people programs. some we're to been demonstrate any going across of clinic of able obviously, So different clinical early encourage comment shown in what our the look across to I which we'll conversations different

heme the in And activity has shown we've cases, indications. -- so these in been, many

I in in And we help going franchise, ]. that to to what's some given patient the create patients partner that's way, areas, populations, be internal order is for our maximize resources would again, how it's and us, our value in a in really both think I effective [ drive has and that able those be, of most So value think clinical commercially most -- do our will in decision-making to that focus those immunology.

Operator

The from next question comes Kelly Shi of Jefferies.

Dingding Shi

STATX your the X/XX now biology or major IL-X/XX also interleukin targeting immunity from are insights besides perspective? [ example, For ] differentiations compared to Congrats progress. in OXXX like innate on targeting of is appreciate ] would I on [ what a the involved STATX signaling.

the its see the based STATX So what indications you breadth do program MOA? on could pursue that of

Nello Mainolfi

bit a this, can I'll you but me. Jared, help of maybe take Yes.

So great question. yes,

studies all, the what shown, others phospho-STATX in And see STATX we immune So block in that of IL-X as that our levels. if IL-X/XX, shown is preclinically reduce you so and we've driven that you really if we've cells receptor activity from not signaling, IL-X shown almost XX. all, have

there read recent same quoting IL-X paper recent on of If that I is of you want receptor reduce if but of function level. the reduction this you receptor signaling. reduce variant this Again, shows keep don't you paper, loss IL-X to the partial STATX, STATX, actually

about talking sorry. gain function humans, functions I'm again, If ThX -- diseases, in you severe gain allergic Also of look STATX have there, at humans, of the biology. human people

eliciting. kind were were biology ThX be -- we expect we of So the to mechanism that

anything feel So receptor. Jared, to it's Okay? like pathway you want IL-X to add? biologically, we on really

Jared Gollob

models. impact no, IL-X, dupi both that And blockade covers are vivo like to I think comparable in seen mean in we that's efficacy that No, it. we've that looked asthma STATX IL-XX And what's in degradation in which models where transcripts dupilumab are [ ] AD resulting phenocopy with was and to induced IL-XX. I in key of to we saw seen been the it expect involved where the we presentation full drugs at our of in AD. in see recent types, our able STATX EADV degradation multiple it symptoms that cell we've human seen and block upregulation sensory pain, even itch in neurons, we in

to XX%, degrade targeting by can has monoclonal from and over think differentiated may addition could with biologics. achieved be sort the an that in STATX pharmacology advantage we able upstream really unique pharmacology be us what of to antibody give being the STATX So XX/X unique of

Operator

question next comes Jeff from Jones Oppenheimer. Our of

Jeffrey Jones

we'll you [ versus platform the Nurix between your on working targeting and aren't the I differentiation both and ]? a small partner, degrader is and on Clearly, ]. stay differentiation the [ Nurix's approach? only Recludix IRAKX between your guess with STATX STATX ones comment Sanofi, here maybe approach and STATX. guys degrader any Could for XXX you molecule And

Nello Mainolfi

Yes.

question. great So

dupilumab that the shown breadth what all to far we've the of would STATX always a phenocopy in I say that STATX company has first, models generated caveat the comparing that and wealth data of can preclinical, there's medicines. a been of both And of we're of approved in variety so while so actually only activity. So data degradation degradation has XXX preclinical, does, depth

an saturating only than in I think so dupilumab as we've block antibody. to way seen some of STATX these that as pharmacological said, would models. But is believe more fully we what And even the dose alpha is degrading -- this IL-X some of that pathway argue receptor a activity that

-- the the would degrader require STATX. that -- hard has that highly pathway that we as in future. With company PD on there past from and No the regards use But in a terms to blockade. at of from made given the be block inhibitor me to You us you is PK data. a that patient understand more or profound and correlation, to PK other potent candidates. other impact development both companies, we has catalytic no much has near it's P also molecule doesn't company blocking are pathway of challenge the any think that small occupancy in a shown based, hear encourage particular have there these other correlation this compound topic I for and even between has what I is -- us can believe to more well and you'll again,

So I are work STATX. you mean, in preclinical that the doing many cited X X companies out are just of

I I've that do that encourage to done. we've companies to other think to what of continue you many since Again, attempting are us. follow we heard shared I'll data,

even beyond hear this our efforts You'll as we STATX more program. XXX in progress about

Operator

question next Joseph The from of JPMorgan. Eric comes

Eric Joseph

of X you're picking you sense IRAKX patient of map Phase and a up Just Phase SAD/MAD both sorry and a trial and road here? I the that numbers of XXX. first -- the half with the the maybe it, which extent evaluating us or give missed readout is whether sort the but in useful X can of on the would include Could cohorts components thereof the with you and I'm readout partial prior in SAD if a dose MAD sort the to number

Nello Mainolfi

miss side, Eric. good the anything, you didn't On

So tell at your this can question. we you about what Jared about least more at can point

Jared Gollob

Yes. the I and color healthy obviously around SAD/MAD single cohorts. dosing both whole of the interrogate your MAD are can't how in provide SAD of IRAKX portions. to being a and Phase is And plan ballpark MAD just the these as we the being But SAD comparison dose actual with reminder, think lot we doses. terms volunteers of of to XX placebo-controlled cohorts I a the the of mean X number probably days

a both we and and include on volunteers. And will MAD efficiently I in we with across doses the doing that portion. plan full SAD of think generate healthy very the the first MAD, going of they'll as SAD year half mentioned, range both readout data and set next data robust So the in

the volunteer So next set of full in it will revealed year. data we the from that healthy be first SAD/MAD half the

Eric Joseph

Very [indiscernible] Excellent. helpful.

Nello Mainolfi

there XXX. add, to to just a I -- SAD patients XXX, we total up or going up is on any roughly days, Yes, Eric, number it's in of and think to few show that in clinicaltrials.gov because maybe the say MAD the sorry, time,

a ahead. you of So we the Do can follow-up? today. Go share that's have piece info additional

Eric Joseph

follow-up, we in year I were any of anyway, here for kind that over looking -- here couldn't next programs find just space with Yes. detail. But Thanks anticipate it. for in going guess, entry. the I&I, should forward additional trial the focus the Yes, we I targets so? the that or

Nello Mainolfi

Yes. I sure. mean, for

we've now We're and it's on working programs. been our -- immunology. many So X-plus effort years we research that in have many, development focused

in -- that development nominated multiple have in few next the months. are past candidates the few being We

when happy we'll again, we're the we've in to to done as -- share happy to the So be as we're targets. close past, clinic, next share

I learned longer a maybe package for should experiences from that target we previous data reasons. competitive also and before we've think our sharing wait our bit

the disclosure. a maybe to at clinic we'll But past. year in bit one closer you expect the next than should So when we're least share

Operator

UBS. The question next of Eli comes from Merle

Unknown Analyst

atopic second, I a ] your little HS the to X for It's expect in into just And on that? portion? then for you following [ those timing And can Phase on SAD/MAD on guess bit STATX, 'XX? readouts confidence of derm Sam move you do on expectations for level IRAKX's versus Eli. any touch patients in how efficacy quickly heading into

Nello Mainolfi

take first then let one. I'll I'll maybe and take the So Jared second, the

I patients To X. -- that said competitive So as we Phase sharing into think we've we yet. to after expect mostly it those plans honest, soon today not be we're said for go reasons, the

those for terms both we'll years. We've to had are, But able closer long-term studies, near-term not development. Jared, the if on months, the share, them. IRAKX? we're eventually in what as for and plans have to them We of development be

Jared Gollob

Yes.

in both know know in toll-like an is there's mechanistically, component a activation. around active of and versus question we confidence being receptors. think have example, IL-XX and well indications. our your mean being of level potentially we HS, level these as in have, IL-X, for in receptor IL-XX, of confidence important of high active terms we I AD, in toll-like IL-X, by HS AD, think Sanofi of I I driven

that X patients, mechanistic we I Phase think HS believing our there's basis I importantly, life and #X pruritus of and in in lesions in did we significantly HS with on both for and pain have AD, that if those AD study also did symptoms skin there. And diseases and on a impact experience these you symptoms these being see look both affect both think of so the where And IRAKX targeting at quality patients. should be effective impacting

in X so pro-inflammatory pathways from patients. showed think and of Phase both I And addition, study, those that modulation of skin we biopsies in

Xb will and have the which question. answer both in the we ultimately think I trials, readouts that clinical to So forward ultimately from Phase look confidence

Operator

question next Guggenheim. The comes Schmidt from from Michael

Michael Schmidt

Another one on XXX, Nello.

a in at safe on-target far. preclinical knockout have expect study what and data, off-target are perhaps So degraders so to from on as based potential XXX the learnings modality might very see clinic? that STATX doses in one AEs And mechanism the obviously perhaps But been models? the high animal what or are

Nello Mainolfi

Yes. Thanks, Mike.

of we degradation, So in preclinical and is full the events. seen what have that exposure even ] terms STATX above which in XX-fold in not [ adverse species -- know degradation reach the we any STATX we

proteomics biological is selective you've an as testing molecule in both XXX as as exceptionally any molecule, other seen, we've done. Our that well

not do any off-target activity. So expect have we to

we hope We the to expect flag. don't is what haven't see for not anything. clinic so anything I we reality have also. terms safety you in to far, seen The in that So of an see answer

of terms only is through partial severe of gain the pathway. STATX, STATX again, already function, also fertile. loss this function have of alpha know mentioned I humans, have that of they so we twice, know which receptor we is know tells don't genetics, this atopic also In you that knockout mice what Again, are really protected, We which, and from diseases, IL-X phenotype. any are normal signaling people

data, look right. we if and say would we're that target, the at perfect hope we our I So the totality of

Michael Schmidt

quick And just follow-up. a

terms think of AD know I Would studies, about there's you move So inflammation. work potential indications? out how you perhaps? on prioritizing lung subsequent of a in STATX lot into do in first, there

that is potential plan asthma, How So you of do prioritizing on top the opportunities? list?

Nello Mainolfi

I to drug. a I mean, going not not don't premature ThX can Yes. ThX this at we're have point. development it. because not AD believe again, it's asthma as drug. is say I disclose we a our This this that drug an we clinical -- is It's This plan, look, drug. just or an But mentioned is earlier,

to So the drug that this has worked opportunity in. work all indications these in dupilumab has

we're most talking also indications recent with data. now So the X X,

be will reasons. the approach to Our larger prioritize indications obvious for

vision ages, be the say. our this severity and would indications. of all committed COPD all asthma, to for for should diseases. program, likely all primary we AD, helping of this of But So are I franchise, patients mission That's

people soon to biologics on do as the to the that so as And possible, to possible going as or many on as unlike are market. much the now be we market help are

Operator

Partners. Faisal comes question next The from from Khurshid Leerink

Faisal Khurshid

I might ask realize I be this premature, to but wanted anyways.

best partnership about on do KT-XXX? when thinking time And you be? are for how So would you the that opportunities think

Nello Mainolfi

It's premature, One we're but not because we're is do to discuss. answer, question. planning answer be, will to thinking actually, a good But to not it's so, that. not good about it

and -- be will our exceptionally to franchise to discussions the premature believe, be personally, we're positioned the I we So have KT-XXX will in future. point. develop believe best it through believe next near it We inflection these

compelling, Phase that think plan take have we I Xb studies. us a through great will hopefully, development some

X value to in our -- think as pipeline, be on commercializes go Phase commercialization, questions based product our and of patients. I will these capital, cost amazing and create impact all commercialization become path is that nearing we're what One the to way be and the this companies everywhere. best and will

is been us multiple partner [ path and to extremely will Another partner particular find going an times, helps an probably be this regions. bar for to high drug be to ], a understatement. commercialize in asked we've STATX it's But us that

Operator

question next Research. comes Chen from from The Wolfe Andy

Unknown Analyst

for on IRAKX for trial here Thanks [indiscernible] It's design changes. clarification Andy. the

previous they So previous that AD. a dose are is doses safe. Sanofi to is too the are HS guess the both deciding unsafe? or doses safe adding and very Are too add additional to dose they think Our because an

new So to is new in higher doses, us trials or that me? it assume can these guys -- these doses safe hear you for both

Nello Mainolfi

yes. Yes,

anything got point. I you -- else? yes, you stopped think think to we at I did some have

Unknown Analyst

Okay.

in higher can doses are assume for both because to higher? are the it this trials the wrong? we us new Or of safe go So thinking that efficacy is

Nello Mainolfi

So question, actually. it's a great

actually, we today. didn't so times, because take talked let's -- maybe this about back So for because a we've step many we

this look we early to and to use in data the investment that remind And will I supportive and early decided not an year an that -- in got efficacy safety point overall accelerate profile at efficacy that investment decided data Sanofi do to actually. elected make point, decision, increased the of again, to the line. to to the the or drug time was and -- set both So development that everybody to a of safety how IA data

haven't you publicly, we or it's whether And so, thousand lower dose, can think speculate a I things. higher what a said

the what for to said driven needs we've regulatory before think though selecting a or I another publicly is need dose dose to dose-ranging conduct that Phase from desire was the X. add studies

X to less move safe. so probably, into so maybe you've studies that more is of box hypothesis add dose not your late checked into neither And they order in it about, Phase was it's safe and wanted to another that too or development

I about think compelling enough the was that saw both accelerating it that study. the we was data

the thank was our I for wanted question. last everybody So joining call. to I think this

work. And As year. we're We've they I at reachable is our easily some know, to Kymera. from exciting follow-up been do again early if probably amazing questions never busier there looking an next externally. want forward and any stakeholders continue thank our all year-end team to you because to

everybody so, busy I think is says good. And

the to next So looking forward update.

Operator

today's concludes This presentation.

You may now disconnect.

Kymera Therapeutics (KYMR) 31 Oct 242024 Q3 Earnings call transcript